@rouchelles.bsky.social
📤 7
📥 38
📝 9
Thank you Irene Fernandez-Ruiz for this great piece of commentary in
@natrevcardiol.nature.com
on the IVORY trial published in
@natmed.nature.com
Main paper can be found here:
rdcu.be/eX8W3
@ziadmallat.bsky.social
@18fdg.bsky.social
@vpd-hlri.bsky.social
@medcambridge.bsky.social
add a skeleton here at some point
20 days ago
0
7
4
reposted by
VPD Heart & Lung Research Institute
23 days ago
Fresh off her
@naturemedicine.bsky.social
paper.
@rouchelles.bsky.social
talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome. Read more ⬇️
rdcu.be/eX8W3
@nihr.bsky.social
@royalpapworth.bsky.social
loading . . .
1
7
4
reposted by
Charlotte Summers
23 days ago
Please do have a listen to
@rouchelles.bsky.social
sharing her thoughts about her science, balancing a clinical academic career in cardiology with family life, & the importance of mentors and a supportive environment.
@nihr.bsky.social
@royalpapworth.bsky.social
@cam.ac.uk
add a skeleton here at some point
1
3
1
Thank you Elisa Martini for featuring the IVORY trial published in
@natmed.nature.com
in Nature Portfolio’s Nature CVR 🫀 Main paper:
rdcu.be/eX8W3
Commentary:
rdcu.be/eYyG6
@jch403.bsky.social
@ziadmallat.bsky.social
@18fdg.bsky.social
@ivorytrial.bsky.social
@mallatlab.bsky.social
24 days ago
0
4
4
reposted by
Nature Medicine
25 days ago
In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y
0
6
6
reposted by
James Rudd
28 days ago
Amazing to be part of this team - please read the paper and let us know what you think!
@rouchelles.bsky.social
add a skeleton here at some point
0
1
1
reposted by
about 1 month ago
A potential breakthrough in heart disease Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine Over 2 years Drug group: 0 events, placebo 11%
www.nature.com/articles/s41...
#HeartHealth
loading . . .
Client Challenge
https://www.nature.com/articles/s41591-025-04090-y
0
1
1
The IVORY trial was published in Nature Medicine last week.
rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a ⬆️ Regulatory T cells ⬇️ Arterial inflammation 🔥 ⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
about 1 month ago
1
1
2
Thank you
@vpd-hlri.bsky.social
for the shout-out. Original article here:
rdcu.be/eX8W3
add a skeleton here at some point
about 1 month ago
0
2
2
Original article:
rdcu.be/eX8W3
add a skeleton here at some point
about 1 month ago
0
0
1
reposted by
PARCC
about 1 month ago
Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation. Learn More:
www.nature.com/articles/s41...
loading . . .
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine
In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...
https://www.nature.com/articles/s41591-025-04090-y
0
4
4
reposted by
Daniel Drucker
about 1 month ago
After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation.
www.nature.com/articles/s41...
loading . . .
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine
In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...
https://www.nature.com/articles/s41591-025-04090-y
1
5
3
Delighted to share that the results of the IVORY trial were published in Nature Medicine:
rdcu.be/eX8W3
This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.
loading . . .
Client Challenge
https://rdcu.be/eX8W3
about 1 month ago
0
2
1
you reached the end!!
feeds!
log in